{"id":"W4324136549","doi":"10.1200/jco.2023.41.6_suppl.605","title":"Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Exelixis","keywords":"Medicine; Clinical endpoint; Population; Internal medicine; Placebo; Hazard ratio; Ipilimumab; Surgery; Nivolumab; Randomized controlled trial; Urology; Gastroenterology; Confidence interval; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001701854,0.0007681531,0.001217869,0.0002733368,0.0002917234,0.0006774166,0.0005339539,0.0008397388,0.00265533],"category_scores_gemma":[0.001022523,0.0002840049,0.001488894,0.0004037228,0.0004828677,0.00039725,0.0003566361,0.00161721,0.0002938462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001068995,"about_ca_system_score_gemma":0.001318108,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001649505,"about_ca_topic_score_gemma":0.006167069,"domain_scores_codex":[0.9994733,0.0002981782,0.00002487624,0.00006600798,0.00006277963,0.0000748805],"domain_scores_gemma":[0.9994337,0.00008869939,0.0001885306,0.00003958991,0.0000351321,0.0002143458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9451033,0.004515401,0.01012141,0.0005591389,0.001701587,0.00006491257,0.00007121858,0.00120473,0.006704563,0.0002236862,0.003262771,0.02646732],"study_design_scores_gemma":[0.7429908,0.1813139,0.062888,0.0001393899,0.003097881,0.0003399806,0.00006669666,0.002474353,0.002142439,0.0004749341,0.004014949,0.00005671792],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927313,0.002880429,0.0002086763,0.0002922792,0.00007546569,0.0006996593,0.001117629,0.00005443422,0.001940079],"genre_scores_gemma":[0.9950662,0.0007538598,0.0005447524,0.0004403008,0.00008651625,0.0006178771,0.001787586,0.00001112679,0.0006918037],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00265533,"threshold_uncertainty_score":0.009000361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2303979398076087,"score_gpt":0.574612994244477,"score_spread":0.3442150544368683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}